Enjoy complimentary customisation on priority with our Enterprise License!
The Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market size is estimated to grow by USD 5.43 billion, at a CAGR of 8.14% between 2022 and 2027. The expansion of the non-Hodgkin lymphoma treatment market is influenced by various factors. This includes recent approvals and a robust pipeline, catering to the needs of patients. Additionally, the increasing elderly population contributes to market growth, as age is a significant risk factor for this condition. Special drug designations further bolster market prospects by incentivizing innovation and development. Despite potential challenges like limited treatment accessibility, positive market trends persist. These trends include growing cancer awareness among the general population and substantial research grants and funding, driving advancements in non-Hodgkin lymphoma therapeutics. As awareness grows and funding increases, the non-Hodgkin lymphoma treatment market is poised for sustained growth, catering to the evolving needs of patients and healthcare providers alike.
To learn more about this report, Request Free Sample
The market is witnessing remarkable progress with the introduction of innovative treatments and platforms such as NHL drugs and the uAIFI Technology Platform alongside the uExcel Technology Platform. As detailed in the Oncology Journal, these advancements are revolutionizing the treatment of non-Hodgkin's lymphoma, offering new hope for patients combating this challenging disease. With a focus on improving outcomes and patient care, these developments mark significant strides in addressing Non-Hodgkin lymphoma disease and advancing cancer treatment.
This market forecasting report extensively covers market segmentation by distribution channel (hospital pharmacy, retail pharmacy, online pharmacy, and others), therapy (immunotherapy, targeted therapy, and chemotherapy), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges.
The market share growth by the hospital pharmacy segment will be significant during the forecast period. The hospital pharmacy is the department of the hospital that deals with the procurement, storage, compounding, dispensing, manufacturing, testing, packaging, and distribution of drugs. Drug distribution systems in hospitals are classified into in-patient and out-patient. The hospital pharmacist is competent in drug procurement, handling, pricing, and dispensing.
Get a glance at the market contribution of various segments Request a PDF Sample
The hospital pharmacy segment was valued at USD 3.60 billion in 2017. However, the drugs used in the treatment of non-Hodgkin lymphoma require skilled hospital pharmacists to provide a proper description of the non-Hodgkin lymphoma treatment drugs. Therefore, hospital pharmacy is expected to be the primary distribution channel for non-Hodgkin lymphoma treatment drugs, which will contribute to the growth of the hospital pharmacy segment of the market during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
North America is estimated to contribute 41% to the growth of the global non-Hodgkin lymphoma treatment market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the non-Hodgkin lymphoma (NHL) therapeutics market during the forecast period. The growth of the market in this region is primarily driven by the sales of approved therapeutics for the treatment of various subtypes of non-Hodgkin lymphoma and the increasing prevalence of various hematologic cancer types, including non-Hodgkin lymphoma. Moreover, non-Hodgkin lymphoma is the 8th most prevalent cancer type in the US, which is the major market shareholder in North America. According to the American Cancer Society's estimates for 2022, non-Hodgkin lymphoma is one of the most common cancers in the US, accounting for about 4% of all cancers. Such a high prevalence of the disease demands advanced and specialized treatment options. Targeted therapies, such as VELCADE and CALQUENCE, have the potential to meet this requirement. Hence, the high prevalence of non-Hodgkin lymphoma is expected to drive the growth of the market in North America during the forecast period.
The market is rapidly advancing with innovative treatments like Lisocabtagene maraleucel and Axicabtagene ciloleucel, transforming outcomes for patients with hematologic malignancy. Radiotherapy (RT), including Intensity-modulated radiation therapy, remains a cornerstone in Non-Hodgkin lymphoma (NHL) treatment. Cutting-edge platforms like uAIFI Technology and uExcel Technology enhance precision in cancer treatment, reflecting the commitment of organizations like the American Society of Hematology. As healthcare systems adapt, these therapies promise improved outcomes for localized lymphomas and broader effectiveness against various cancer cases. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The recent approvals and strong pipeline are key factors driving the growth of the market. Although many approved therapies are available for various types of blood cancer, the market experiences a huge unmet need for their treatment. Currently, many chemotherapy drugs are dominating the treatment landscape for several types of cancer. However, in the market, targeted and immunotherapies have a higher share compared with chemotherapies.
This can be attributed to limitations such as the long-lasting adverse effects of chemotherapies, which reduce patient adherence to the treatment. Moreover, targeted therapies and immunotherapies have emerged as a prevailing class of therapeutics, acting through the regulation of specific proteins and protein targets. The growing R&D in this space and ongoing clinical trials of late-stage molecules further support the growth prospects of the global non-Hodgkin lymphoma treatment market.
Growing awareness about cancer is the primary trend in market growth. The rise in awareness about cancer is one of the major trends driving the growth of the market. Various international and national-level campaigns are conducted to increase awareness about cancer and help early detection of the disease. For instance, organizations such as the American Social Health Association (ASHA) and the National Cervical Cancer Coalition (NCCC) implement initiatives to create awareness about the prevention and control of cervical cancer. Similarly, the CDC provides guidelines and conducts awareness programs to screen and vaccinate underserved individuals with cervical cancer.
Furthermore, Cancer Breakthroughs 2020, previously known as Cancer Moonshot 2020, is an initiative taken by the US government in 2016 for the development of research on vaccine-based immunotherapies to fight cancer. The aim of this project is to make therapies available to more patients while detecting the disease at an early stage. By inviting the pharmaceutical players to join the initiative, the Cancer Breakthroughs 2020 program plans on making the targeted therapies one of the major areas of focus of this project. Collectively, these initiatives are expected to increase awareness about cancer and the available treatments, and the market during the forecast period.
Limited access to treatment is a major challenge to the growth of the market. One of the major challenges faced by the market is limited access to treatment for most patients across the world. Most countries in North America and Europe have almost all the approved drugs for the treatment of non-hodgkin lymphoma. However, therapeutic options for the treatment of diseases are limited in developing and underdeveloped economies. Despite the high prevalence of various blood cancers, including non-hodgkin lymphoma, in these countries, the inadequate availability of treatment options makes it difficult for patients to undergo treatment on time. The high cost of therapeutics also makes treatment unaffordable to a significant share of the patient population in these countries, especially due to the unavailability of patient assistance programs, poor understanding of health insurance, and the lack of advanced healthcare infrastructure.
Moreover, the lack of advanced healthcare infrastructure and limited awareness about the disease are delaying treatment, which, in turn, is making treatment with a limited number of chemotherapies ineffective. A major share of the patients in India is from backward regions, which have limited access to the treatment of cancer indications. Various countries in Asia, South America, and Africa also face similar challenges. These factors are expected to hinder the growth of the market significantly during the forecast period.
The market research report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market forecast report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AstraZeneca Plc - The company offers non-Hodgkin lymphoma therapeutics such as T-cell engagers which are bispecific molecules that are engineered to redirect the immune systems to recognize and kill cancer cells. Also, they engage in the discovery, development, manufacturing, marketing, and sale of pharmaceutical products.
The market report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Million" for the period 2023 to 2027, as well as historical data from 2017 to 2022 for the following segments.
The market is undergoing transformative changes with the advent of cutting-edge treatments such as CAR T-cell therapy and immune checkpoint inhibitors. These therapies target signaling pathways and genetic mutations specific to different NHL subtypes, offering tailored approaches for patients. Advancements in precision medicine enable the identification of molecular subtypes and genetic abnormalities, guiding treatment decisions. Additionally, diagnostic techniques facilitate early detection and monitoring. With the rise in B cell lymphomas and T cell lymphoma incidences, pharmaceutical companies, research institutions, and healthcare policies focus on developing innovative therapies like C-CAR039 and Rituximab, ensuring better outcomes for patients.
Further, in the market, addressing toxicities associated with treatments like Chimeric antigen receptor (CAR) T-cell therapies remains crucial. Retail pharmacies & drug stores, hospital pharmacies, and online pharmacies play pivotal roles in distributing medications. The increasing incidence of non-Hodgkin lymphoma prompts intensified research and regulatory scrutiny by the Food and Drug Administration (FDA). Therapies targeting CD19 and CD20 antigens offer hope for patients with diffuse large B cell lymphoma (r/r DLBCL) and mantle cell lymphoma (MCL). Monoclonal antibodies and Proton therapy represent evolving treatment modalities, often combined with other therapies for enhanced efficacy in T-cell lymphoma and B-cell lymphoma cases. Customization of radiation doses ensures optimized treatment outcomes, reflecting the dynamic landscape of lymphoma therapeutics.
Market Scope |
|
Report Coverage |
Details |
Page number |
174 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 8.14% |
Market growth 2023-2027 |
USD 5.43 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
7.6 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 41% |
Key countries |
US, Canada, UK, Germany, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AstraZeneca Plc, Baxter International Inc., Bayer AG, BeiGene Ltd., Biogen Inc., Bristol Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Get access to Report Sample PDF!
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Therapy
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.